Cantargia – executive interview

Cantargia – executive interview

Cantargia — 8 videos in collection

More on this equity

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme; the most advanced indications are non-small cell lung cancer and pancreatic cancer. CAN10, the company’s second lead asset, is being developed for autoimmune diseases. In this video, Cantargia’s chief executive officer Göran Forsberg provides an update on the recently announced rights issue and key clinical highlights.


You may also be interested in these:

Healthcare

Cantargia – executive interview

Healthcare

Cantargia: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free